Prognostic role of neutrophil-to-lymphocyte ratio (NLR) in urological tumors: an umbrella review of evidence from systematic reviews and meta-analyses

Authors

  • Georges Mjaess Department of Urology, University Clinics of Brussels, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium; Hotel-Dieu de France, University of Saint Joseph, Beirut, Lebanon
  • Roy Chebel Hotel-Dieu de France, University of Saint Joseph, Beirut, Lebanon
  • Aya Karam Hotel-Dieu de France, University of Saint Joseph, Beirut, Lebanon
  • Ilan Moussa Department of Urology, University Clinics of Brussels, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
  • Dominique Pretot Department of Urology, University Clinics of Brussels, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
  • Georges Abi Tayeh Hotel-Dieu de France, University of Saint Joseph, Beirut, Lebanon
  • Julien Sarkis Hotel-Dieu de France, University of Saint Joseph, Beirut, Lebanon
  • Albert Semaan Hotel-Dieu de France, University of Saint Joseph, Beirut, Lebanon
  • Alexandre Peltier Department of Urology, Institut Jules Bordet, Brussels, Belgium
  • Fouad Aoun Hotel-Dieu de France, University of Saint Joseph, Beirut, Lebanon; Department of Urology, Institut Jules Bordet, Brussels, Belgium
  • Simone Albisinni Department of Urology, University Clinics of Brussels, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
  • Simone Albisinni Department of Urology, University Clinics of Brussels, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
  • Thierry Roumeguère Department of Urology, University Clinics of Brussels, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium; Department of Urology, Institut Jules Bordet, Brussels, Belgium

DOI:

https://doi.org/10.1080/0284186X.2021.1886323

Keywords:

Neutrophil-to-lymphocyte ratio, bladder cancer, prostate cancer, kidney cancer, upper tract carcinoma

Abstract

Background

Neutrophil-to-lymphocyte ratio (NLR) has been studied as a biomarker for cancer prognosis, predicting survival in many tumors. The aim of this umbrella review was to combine the results from all systematic reviews and meta-analyses related to the prognostic role of the NLR in patients with urological tumors.

Methods

A PubMed, Scopus, Embase and Cochrane search was undergone from inception through September 2020 for systematic reviews and meta-analyses investigating the prognostic value of NLR in urological tumors, subdivided into prostate cancer, renal cell carcinoma, urothelial bladder and upper tract carcinomas PROSPERO (CRD42020216310).

Results

The results have shown, with a high level of evidence, that an elevated NLR predicts worse overall survival (OS), progression-free survival (PFS) and relapse-free survival (RFS) in prostate cancer, worse OS, PFS and RFS in renal cell carcinoma, worse OS, PFS, RFS and cancer-specific survival (CSS) in muscle invasive bladder cancer, worse PFS and RFS in non-muscle invasive bladder cancer, and worse OS, PFS, RFS and CSS in urothelial upper tract carcinoma.

Conclusion

NLR has a significant prognostic value in urological tumors and should be included in prognostic scores of these cancers.

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2021-06-03

How to Cite

Mjaess, G., Chebel, R., Karam, A., Moussa, I., Pretot, D., Abi Tayeh, G., … Roumeguère, T. (2021). Prognostic role of neutrophil-to-lymphocyte ratio (NLR) in urological tumors: an umbrella review of evidence from systematic reviews and meta-analyses. Acta Oncologica, 60(6), 704–713. https://doi.org/10.1080/0284186X.2021.1886323

Issue

Vol. 60 No. 6 (2021): Acta Oncologica

Section

Articles